First-Line TKI Plus Up-Front Local Radiotherapy Improves Survival in EGFR+ NSCLC

Patients with EGFR-mutated non–small cell lung cancer had an improved survival benefit following treatment with a first-line tyrosine kinase inhibitors plus up-front local radiotherapy.

Adding up-front local radiotherapy to a first-line tyrosine kinase inhibitor (TKIs) improved progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutated non–small cell lung cancer, according to the results of the phase 3 SINADS trial (NCT02893332).

The pre-specified interim analysis found patients who were receiving only TKIs had a median PFS of 12.5 months (95% CI, 11.6-13.4) vs 20.2 months (95% CI, 17.9-22.5) for those receiving TKIs plus radiotherapy (HR, 0.22; 95% CI, 0.17-0.46; P <.001). The median OS for the TKI group was 17.6 months (95% CI, 15.4-19.8) vs 25.5 months (95% CI, 23.2-27.8) for the TKI plus radiotherapy group (HR, 0.44; 95% CI, 0.28-0.68; P <.001).

A total of 133 patients were randomized to either the TKI-only group (n = 65) or the TKI plus radiotherapy group (n = 68). Because of the results from this analysis, the ethics committee did not recommend additional recruitment for the trial. The cutoff for treatment was 1 year, and the median follow-up was 23.6 months.

In terms of patient characteristics, 73.1% of patients in the TKI group had bone metastases vs 68.9% in the TKI plus radiotherapy group. Other areas of oligometastatic lesions included the abdomen (18.8% vs 18.0%) and the contralateral lung (6.9% vs 9.6%). Ninety-two patients had an EGFR abnormality in exon 19. Additionally, investigators more commonly treated patients with gefitinib (52.6%) and erlotinib (39.8%) vs icotinib. The most common radiotherapy doses included 30 Gy in 53.5% of fields, and 25 Gy in 31.0% of fields.

In 36 patients in the TKI group vs 62 in the TKI plus radiotherapy, local control of primary tumor and metastases was achieved at the last follow-up (P <.001). The 6-month PFS rate was 95.2% (95% CI, 93.6%-96.9%) in the TKI group and 99.1% (95% CI, 98.7-99.5%) in the TKI plus radiotherapy group (P >.05).

At the time this analysis was conducted, 93 patients had died. Additionally, 38 patients in the TKI-only arm underwent palliative radiotherapy to manage symptoms, 6 of whom underwent radiofrequency ablation.

The post-hoc analysis identified several independent predictors of PFS, including Zurbod performance status (P = .02), number of metastases (P = .004), and radiotherapy (P = .005). Additionally, the independent factor of OS included Zubrod performance status (P = .02), T stage (P = .02), number of metastases (P = .004), mutation type (P = .001), and radiotherapy (P = .004).

Adverse effects relating to TKI treatment included skin reactions in both groups. Three patients in the TKI-only group and 5 in the TKI plus radiotherapy group required dose reductions, with 1 and 2 patients in both respective groups discontinuing treatment. Grade 3/4 skin toxicity was reported in 10 patients in the TKI group and 8 patients also developed grade 3/4 pruritus. Among those in the TKI plus radiotherapy group, 10 patients developed grade 3/4 skin rash, and 5 patients had grade 3/4 pneumonitis.

Moreover, 1 patient had a fractured rib that was attributed to chest radiotherapy. Two patients needed long-term pain management after receiving radiotherapy, with 1 patient having nephrolithiasis, and the other having herpes zoster that was deemed unrelated to treatment.


Wang XS, Bai YF, Verma V, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J Natl Cancer Inst. Published Online January 30, 2022. doi:10.1093/jnci/djac015

Related Videos
An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.
Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non-small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Data from the phase 3 LUSTRE trial indicated that stereotactic body radiotherapy is a safe and effective alternative to conventional radiation for use in patients with stage I medically-inoperable non-small lung cancer, according to an expert from Juravinski Cancer Centre in Canada.
Hossein Borghaei, DO, MS, discussed where investigators may drive future research following the phase 2 Lung-MAP trial examining pembrolizumab and ramucirumab in previously treated advanced non–small cell lung cancer.
Hossein Borghaei, DO, MS, highlights data that read out of the phase 2 Lung-MAP trial, assessing ramucirumab/pembrolizumab in previously treated advanced non–small cell lung cancer.
Related Content